A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

7140

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis Cardiovascular Disease
Chronic Kidney Disease

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company